ArticleRegional anesthesia and pain medicine2026
Intravenous methocarbamol for acute pain after spine surgery: a target trial emulation.
Article in Regional anesthesia and pain medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06659965 (Intravenous Methocarbamol for Acute Pain After Spine Surgery), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intravenous Methocarbamol for Acute Pain After Spine Surgery
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSkeletal muscle relaxants are often included in multimodal analgesic regimens following spine surgery, but their actual effectiveness remains unclear due to limited and inconsistent evidence. We aimed to evaluate the effectiveness of intravenous methocarbamol in reducing acute postoperative pain and opioid consumption after elective spine surgery.
methodsThis emulated target trial used electronic health record data from patients undergoing elective spine surgery (posterior spinal fusion, anterior cervical discectomy and fusion, laminectomy/laminotomy) between January 1, 2020 and December 31, 2023. The exposure was intravenous methocarbamol (≥500 mg) administered within 2 hours postoperatively compared with usual care without methocarbamol. The primary outcome was the time-weighted average pain score in the 6-hour follow-up window after treatment assignment. The secondary outcome was cumulative opioid use measured in oral morphine equivalents (OMEs) over the same period. We used 1:1 time-varying propensity score matching to adjust for confounding.
resultsThe matched cohort included 1270 patients (median (IQR) age, 61 (50-68) years; 765 (60.2%) female). Administration of intravenous methocarbamol was not associated with significant reductions in postoperative pain scores (adjusted mean difference, 0.1; 95% CI, -0.1 to 0.4) or opioid consumption (adjusted mean difference, 0.6 OME; 95% CI, -1.4 to 2.5) compared with controls. Sensitivity analyses generally confirmed primary results, except the marginal structural model indicated slightly increased pain scores in the methocarbamol group (adjusted mean difference, 0.5; 95% CI, 0.3 to 0.7), though this was not clinically meaningful.
conclusionsIn this emulated target trial of elective spine surgery, intravenous methocarbamol did not reduce acute postoperative pain or opioid consumption. These findings suggest a lack of analgesic benefit from intravenous methocarbamol use after spine surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.